Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
Source: SeekingAlpha
2026-03-07 09:20:50 ET
More on Incyte, Novo Nordisk, etc.
- CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- MacroGenics drops after FDA partial clinical hold on lead program
- Novo’s China obesity drug posts positive mid-stage trial results
Read the full article on Seeking Alpha
For further details see:
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
Incyte Corporation
NASDAQ: INCY
INCY Trading
1.53% G/L:
$97.48 Last:
328,276 Volume:
$97.52 Open:
INCY Latest News
March 06, 2026 04:42:00 pm
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY Stock Data
$19,951,294,692
161,377,262
0.07%
384
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
